RIT2 (Ras-like in neurons) antibodies are specialized research tools designed to detect and study the RIT2 protein, a small GTPase critical for neuronal signaling, autophagy regulation, and Parkinson’s disease (PD) pathology . These antibodies enable precise visualization and quantification of RIT2 in biochemical assays, immunohistochemistry (IHC), and molecular studies. RIT2 is enriched in dopaminergic neurons of the substantia nigra (SNc) and interacts with LRRK2 kinase, α-synuclein (aSyn), and autophagy-lysosomal pathway (ALP) components .
RIT2 antibodies are employed in diverse experimental workflows:
Localizes RIT2 in mouse pancreas and brain tissue (e.g., SNc dopaminergic neurons) .
Requires antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0) .
RIT2 antibodies have elucidated critical roles of RIT2 in neurodegeneration:
LRRK2 Kinase Modulation: RIT2 overexpression reduces LRRK2 kinase activity (pS1292-LRRK2) and rescues autophagy-lysosomal deficits in G2019S-LRRK2 cells .
α-Synuclein (aSyn) Aggregation: RIT2 overexpression diminishes pS129-aSyn inclusions and protects against A53T-aSyn-induced neurodegeneration in vivo .
Lysosomal Function: RIT2 enhances lysosomal biogenesis, reduces lysosome size, and increases proteolytic activity (DQ-Red-BSA assay) .
RIT2 upregulates MiT/TFE3 transcription factors, promoting ALP gene expression (e.g., lysosomal hydrolases) .
RIT2 deficiency mimics ALP defects seen in PD models, highlighting its role in proteostasis .